1[1]Brown MS, Goldstein JL. Lipoprotein metabolism in the macrophage: implications for cholesterol deposition in atherosclerosis. Annu Rev Biochem, 1983, 52: 224～261.
2[2]McMurrag HF,Parthasarathy S,Steinberg D.Oxidatively modified low density lipoprotein is a chemoattractant for human T lymphocytes. J Clin Invest, 1993,92:1004 ～ 1008.
3[3]Reid VC,Mitchinson MJ,Skepper JN. Cytotoxicity of oxidized low-density lipoprotein to mouse peritoneal macrophages: an ultrastructural study. J Pathol. 1993,171: 321～328.
4[4]Hein TW,Kuo L. LDLs impair vasomotor function of the coronary microcirculation. Circ Res, 1998,83:404～414.
5[5]Lehtimaki T. Lehtinen S. Solakivi T, et al. Autoantibodies against oxidized low density lipoprotein in patients with angiographically verified coronary artery disease.Arterioscler Thromb Vasc Biol, 1999,19:23～27.
6[6]Oshima R,Ikeda T,Watanabe K,et al. Probucol treatment attenuates the aortic atherosclerosis in Watanabe heritable hyperlipidemic rabbits. Atherosclerosis, 1998,137:13～22.
7[1]Nagase H.Activation mechanis ms of matrix metalloproteinases.Biol Che m,1997,378:151-160.
8[2]Brew K,Dinakarpandian D,Nagase H.Tissu e inhibitors of metalloproteinases:evolu tion,structure and function.Biochim Biop hys Acta,2000,1477:267-283.
9[3]Rajavashisth TB,Xu XP,Jovinge S.Membra ne type 1 matrix metalloproteinase expre ssion in human atherosclerotic plaques:e vidence for activation by proinflammator y mediators.Circulation,1999,99:3103-310 9.
10[4]Fitzgerald M,Hayward IP,Thomas AC,et al.Matrix metalloproteinase c an facilitate the heparanase-induced pro motion of phenotype change in vascular s mooth muscle cells.Atherosclerosis,1999, 145:97-106.
